- PR Newswire•7 days agoUnited Therapeutics Corporation To Report Fourth Quarter And Annual 2016 Financial Results Before The Market Opens On Wednesday, February 22, 2017
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2017 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) announced today that it will report its fourth quarter and annual 2016 ...
- CNBC•8 days ago
Marathon had said it would charge $89,000 for its Duchenne muscular dystrophy treatment, despite it having sold elsewhere for just $1,000.
- Benzinga•14 days ago
Wedbush’s Liana Moussatos mentioned a slew of potential catalysts that could impact emerging pharmaceutical companies this year. Aimmune Therapeutics Inc (NASDAQ: AIMT ) — Rated Outperform, PT: $42 Potential ...
UTHR : Summary for United Therapeutics Corporation - Yahoo Finance
United Therapeutics Corporation (UTHR)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Ask||181.00 x 100|
|Day's Range||165.76 - 169.89|
|52 Week Range||97.52 - 169.89|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||11.36|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|